ATHA
Athira Pharma Inc.
$3.96
-$0.05(-1.25%)
33
Overall
60
Value
18
Tech
23
Quality
Market Cap
$15.42M
Volume
9.91K
52W Range
$2.20 - $6.68
Target Price
$4.00
Company Overview
| Mkt Cap | $15.42M | Price | $3.96 |
| Volume | 9.91K | Change | -1.25% |
| P/E Ratio | -0.2 | Open | $4.00 |
| Revenue | -- | Prev Close | $4.01 |
| Net Income | $-96.9M | 52W Range | $2.20 - $6.68 |
| Div Yield | N/A | Target | $4.00 |
| Overall | 33 | Value | 60 |
| Quality | 23 | Technical | 18 |
No chart data available
About Athira Pharma Inc.
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Latest News
Athena Gold Closes First Tranche of Private Placement, Upsizes Offering
TipRanks Canadian Auto-Generated Newsdesk•2 days ago
Athena Gold Reports Promising Drilling Results at Excelsior Project
TipRanks Canadian Auto-Generated Newsdesk•15 days ago
Athena Gold Reports Promising Drilling Results at Excelsior Springs Project
TipRanks Canadian Auto-Generated Newsdesk•15 days ago
Athena Gold Upsizes Private Placement Amid Strong Investor Demand
TipRanks Canadian Auto-Generated Newsdesk•17 days ago
Athena Gold Corporation Reports Increased Assets in Q3 2025
TipRanks Auto-Generated Newsdesk•20 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ATHA | $3.96 | -1.2% | 9.91K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |